GlassScriptPhysician profile
Sara Denly
NPI 1649869181
$8,375.18
in general payments reported to CMS, 2019-2025
31 companies · $3,307 in 2025
The $3,307 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $337 · 2023: $2,633 · 2024: $2,098 · 2025: $3,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,064 · Travel and Lodging: $1,558 · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,064.21 |
| Travel and Lodging | $1,558.21 |
| Education | $415.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,033.55 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Inspire Medical Systems, INC. | $1,388.87 | 2024-2025 | Inspire |
| Zoll Respicardia, INC. | $1,274.32 | 2023-2024 | Remede System |
| Harmony Biosciences LLC | $485.09 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $403.29 | 2022-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $398.33 | 2022-2025 | |
| Grifols USA, LLC | $385.23 | 2022-2025 | Prolastin-C Liquid |
| Amgen INC. | $347.05 | 2022-2025 | Tezspire |
| Insmed, INC. | $235.85 | 2024-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $217.68 | 2024-2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.40 | 2022-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $172.00 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $154.56 | 2022-2023 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $84.28 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $77.00 | 2023-2025 | Glassia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $68.60 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Baxter Healthcare | $60.16 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $53.73 | 2023-2024 | Yupelri |
| Verona Pharma, INC. | $50.09 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $44.94 | 2024-2025 | Sunosi |
| Janssen Pharmaceuticals, INC | $33.92 | 2022-2023 | Xarelto |
| Genzyme Corporation | $32.16 | 2024-2025 | |
| Genentech USA, INC. | $30.12 | 2023 | Tecentriq, Xolair |
| Liquidia Technologies, INC. | $22.91 | 2025 | Yutrepia |
| Alexion Pharmaceuticals, INC. | $19.39 | 2024 | Ultomiris |
| Electromed, INC. | $18.24 | 2022 | |
| Viatris Specialty LLC | $16.48 | 2025 | Yupelri |
| Philips North America LLC | $15.85 | 2024 | (Ak6) Vest Therapy |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2022 | |
| Glaxosmithkline, LLC. | $14.23 | 2024 | Nucala |
| Lilly USA, LLC | $13.79 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Denly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.